Compare HUT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | CYTK |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.7B |
| IPO Year | 2023 | 2004 |
| Metric | HUT | CYTK |
|---|---|---|
| Price | $61.43 | $61.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 23 |
| Target Price | ★ $152.78 | $109.40 |
| AVG Volume (30 Days) | ★ 5.2M | 1.8M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $235,118,000.00 | $13,368,000.00 |
| Revenue This Year | $25.69 | $72.63 |
| Revenue Next Year | $94.23 | $181.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $31.67 | $57.92 |
| 52 Week High | $140.80 | $88.31 |
| Indicator | HUT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 30.39 | 37.55 |
| Support Level | $44.69 | $59.21 |
| Resistance Level | $61.59 | $66.63 |
| Average True Range (ATR) | 6.58 | 1.98 |
| MACD | -2.07 | 0.33 |
| Stochastic Oscillator | 0.02 | 31.89 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.